Kuen-Feng Chen Selected Research

Protein Phosphatase 2 (Protein Phosphatase 2A)

1/2017	EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells.
1/2016	SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A.
4/2015	Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy.
8/2014	CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
5/2013	Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
2/2013	Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
1/2013	Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.
7/2012	CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
5/2012	CIP2A is a predictor of poor prognosis in colon cancer.
4/2012	Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kuen-Feng Chen Research Topics

Disease

64	Neoplasms (Cancer) 01/2021 - 02/2004
47	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 08/2008
9	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 04/2014
9	Breast Neoplasms (Breast Cancer) 10/2018 - 04/2005
8	Triple Negative Breast Neoplasms 11/2017 - 04/2012
6	Carcinogenesis 12/2018 - 09/2012
6	Colorectal Neoplasms (Colorectal Cancer) 10/2017 - 08/2014
3	Lung Neoplasms (Lung Cancer) 01/2018 - 10/2017
3	Squamous Cell Carcinoma of Head and Neck 01/2017 - 06/2012
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 06/2013 - 05/2005
2	Cholangiocarcinoma 12/2018 - 10/2018
2	Fibrosis (Cirrhosis) 11/2017 - 06/2015
2	Liver Cirrhosis (Hepatic Cirrhosis) 11/2017 - 06/2015
2	Neoplasm Metastasis (Metastasis) 09/2016 - 01/2016
2	Lymphoma (Lymphomas) 07/2014 - 08/2008
2	Leukemia 07/2014 - 05/2013
2	Hematologic Neoplasms (Hematological Malignancy) 05/2013 - 07/2012
2	Prostatic Neoplasms (Prostate Cancer) 02/2005 - 02/2004
1	Ataxia Telangiectasia (Louis Bar Syndrome) 10/2018
1	Disease Progression 01/2017
1	Obesity 10/2016
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2016
1	Hepatitis B 10/2015

Drug/Important Bio-Agent (IBA)

27	Sorafenib (BAY 43-9006)FDA Link 11/2017 - 01/2010
12	Phosphotransferases (Kinase)IBA 10/2018 - 05/2005
10	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 01/2017 - 04/2012
10	Bortezomib (Velcade)FDA Link 12/2013 - 08/2008
9	Pharmaceutical PreparationsIBA 12/2018 - 11/2010
9	Proteins (Proteins, Gene)FDA Link 11/2017 - 05/2005
8	ErbB Receptors (EGF Receptor)IBA 01/2017 - 04/2012
7	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 06/2017 - 11/2011
7	Phosphoric Monoester Hydrolases (Phosphatases)IBA 09/2016 - 04/2011
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 10/2012
6	Oncogene Proteins (Oncogene Protein)IBA 01/2018 - 05/2012
6	regorafenibIBA 10/2016 - 08/2014
5	protein phosphatase 5IBA 12/2018 - 01/2017
5	obatoclaxIBA 02/2015 - 08/2012
5	SC-2001IBA 07/2014 - 08/2012
4	tissue-factor-pathway inhibitor 2 (PP5)IBA 12/2018 - 01/2017
3	AMP-Activated Protein KinasesIBA 01/2018 - 10/2017
3	Non-Receptor Type 1 Protein Tyrosine PhosphataseIBA 10/2017 - 05/2016
3	p120 GTPase Activating ProteinIBA 10/2017 - 05/2016
3	4- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- oneIBA 01/2016 - 02/2012
3	Proteasome InhibitorsIBA 05/2013 - 08/2008
3	tigatuzumabIBA 02/2013 - 05/2011
2	palbociclibIBA 10/2018 - 01/2017
2	Tyrosine Kinase InhibitorsIBA 11/2017 - 02/2016
2	nintedanibIBA 11/2017 - 07/2014
2	Tyrosine (L-Tyrosine)FDA Link 11/2017 - 05/2005
2	Docetaxel (Taxotere)FDA Link 09/2017 - 01/2017
2	Protein Tyrosine PhosphatasesIBA 06/2017 - 09/2016
2	Lapatinib (GW572016)FDA Link 02/2017 - 02/2016
2	Hormones (Hormone)IBA 01/2017 - 04/2012
2	Biomarkers (Surrogate Marker)IBA 01/2017 - 06/2015
2	Biological ProductsIBA 01/2017 - 12/2014
2	Dasatinib (BMS 354825)FDA Link 01/2017 - 06/2012
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016 - 06/2013
2	Transcription Factors (Transcription Factor)IBA 12/2014 - 04/2014
2	Estrogen ReceptorsIBA 09/2014 - 04/2012
2	Indicators and Reagents (Reagents)IBA 01/2014 - 01/2014
2	Proteasome Endopeptidase Complex (Proteasome)IBA 05/2013 - 01/2013
2	Cyclin D1IBA 01/2013 - 04/2005
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2012 - 04/2009
2	LigandsIBA 03/2012 - 04/2009
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 04/2011 - 04/2009
2	Celecoxib (Celebrex)FDA Link 11/2008 - 02/2004
2	PPAR gammaIBA 04/2005 - 02/2005
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 01/2019
1	CanagliflozinIBA 01/2019
1	Glucose (Dextrose)FDA LinkGeneric 01/2019
1	CateninsIBA 01/2019
1	Serine (L-Serine)FDA Link 12/2018
1	Threonine (L-Threonine)FDA Link 12/2018
1	Cyclin-Dependent Kinase 4IBA 10/2018
1	Carbon Tetrachloride (Tetrachloromethane)IBA 11/2017
1	raf KinasesIBA 09/2017
1	SH2 Domain-Containing Protein Tyrosine PhosphatasesIBA 06/2017
1	Cantharidin (Cantharides)IBA 01/2017
1	norcantharidinIBA 01/2017
1	Small Interfering RNA (siRNA)IBA 01/2017
1	LeptinIBA 10/2016
1	Insulin (Novolin)FDA Link 10/2016
1	GuanosineIBA 05/2016
1	Lactic Acid (Lactate)FDA LinkGeneric 04/2016
1	Pyruvate KinaseIBA 04/2016
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016
1	Androgen Receptors (Androgen Receptor)IBA 10/2015
1	Thioacetamide (Thioacetamid)IBA 06/2015
1	Interleukin-6 (Interleukin 6)IBA 06/2015
1	indoleIBA 02/2015
1	PyrrolesIBA 02/2015
1	ProdigiosinIBA 02/2015
1	CopperIBA 02/2015
1	AfatinibIBA 02/2015

Therapy/Procedure

13	Therapeutics 10/2018 - 08/2012
3	Radiotherapy 10/2018 - 07/2014
2	Ligation 11/2017 - 06/2015
1	Castration 10/2015
1	Metastasectomy 04/2015